Cellectar Biosciences to Present at the 2016 Biotech Showcase
07 Januar 2016 - 2:30PM
Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused
biotechnology company, announces today its CEO, Jim Caruso, will be
presenting at the Biotech Showcase in San Francisco on January 12,
2016 at 5:00 PM PT in the Mission I room.
“The Biotech Showcase is an important industry gathering,
uniting a unique combination of established and emerging company
participants with a diverse group of investors,” said Mr.
Caruso. “With our recent announcements regarding the
successful advancement of our multiple myeloma program and initial
corporate collaboration to research a series of chemotherapeutics
in combination with our PDC delivery platform, we welcome the
opportunity for Cellectar to further update the investment
community on our continued progress.” Following the presentation, a
link to the latest presentation, including both slides and audio,
will be posted on the company’s website.
About Cellectar Biosciences, Inc. Cellectar
Biosciences is developing phospholipid drug conjugates (PDCs)
designed to provide cancer targeted delivery of diverse oncologic
payloads to a broad range of cancers and cancer stem cells.
Cellectar's PDC platform is based on the company's proprietary
phospholipid ether analogs. These novel small-molecules have
demonstrated highly selective uptake and retention in a broad range
of cancers. Cellectar's PDC pipeline includes product candidates
for cancer therapy and cancer diagnostic imaging. The Company's
lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic
radioisotope, as its payload. CLR 131 is currently being evaluated
under an orphan drug designated Phase 1 study in patients with
relapsed or refractory multiple myeloma. The company is also
developing PDCs for targeted delivery of chemotherapeutics such as
paclitaxel (CLR 1603-PTX), a preclinical stage product candidate,
and plans to expand its PDC chemotherapeutic pipeline through both
in-house and collaborative R&D efforts. For additional
information please visit www.cellectarbiosciences.com.
This news release contains forward-looking statements. You can
identify these statements by our use of words such as "may,"
"expect," "believe," "anticipate," "intend," "could," "estimate,"
"continue," "plans," or their negatives or cognates. These
statements are only estimates and predictions and are subject to
known and unknown risks and uncertainties that may cause actual
future experience and results to differ materially from the
statements made. These statements are based on our current beliefs
and expectations as to such future outcomes. Drug discovery and
development involve a high degree of risk. Factors that might cause
such a material difference include, among others, uncertainties
related to the ability to raise additional capital, uncertainties
related to the ability to attract and retain partners for our
technologies, the identification of lead compounds, the successful
preclinical development thereof, the completion of clinical trials,
the FDA review process and other government regulation, our
pharmaceutical collaborators' ability to successfully develop and
commercialize drug candidates, competition from other
pharmaceutical companies, product pricing and third-party
reimbursement. A complete description of risks and uncertainties
related to our business is contained in our periodic reports filed
with the Securities and Exchange Commission including our Form
10-K/A for the year ended December 31, 2014. These
forward-looking statements are made only as of the date hereof, and
we disclaim any obligation to update any such forward-looking
statements.
INVESTOR AND MEDIA CONTACT:
Jules Abraham
JQA Partners
917-885-7378
jabraham@jqapartners.com
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
Von Jul 2023 bis Jul 2024